Thermo Fisher Scientific Extends Reach in Pharma, Biotech with PPD Acquisition

Facebook X LinkedIn Email
WALTHAM, Mass., April 15, 2021 — Thermo Fisher Scientific is acquiring PPD Inc., a provider of clinical research services to the pharma and biotech industry. The companies’ boards of directors approved an acquisition agreement worth $17.4 billion and $47.50 per share, as well as Thermo Fisher’s assumption of approximately $3.5 billion of net debt. PPD will become part of Thermo Fisher’s laboratory products and services segment.

In a press release, Thermo Fisher said the acquisition provides it with a drug development platform, patient recruitment capabilities, and laboratory services, supporting its capabilities in pharma and biotech.

The transaction is expected to close by the end of 2021.

Published: April 2021
mergers & acquisitionsacquisitionsThermo FisherThermo Fisher ScientificThermo Fisher Scientific Inc.Americaslife sciencesmedicalmedical instrumentationmedicineBiophotonicsbiotechpharma

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.